WSTAM
CLSD

Wilbanks Smith & Thomas Asset Management’s Clearside Biomedical CLSD Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7
Closed -$1K – 519
2018
Q3 		$1K Buy
+7
New +$832 ﹤0.01% 1500

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's CLSD Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Clearside Biomedical (CLSD) in Q4 2018, closing a stake of 7 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in CLSD in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 69 funds tracked by Wall St. Rank hold CLSD as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Clearside Biomedical position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 7 Clearside Biomedical shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Clearside Biomedical in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Clearside Biomedical position peaked at $1K in Q3 2018.
  • 69 funds tracked by Wall St. Rank held Clearside Biomedical as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.